Maklitio 20 mg Oral FC tablet.
PDF Leaflet Revision Date: 30 May 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of pulmonary arterial hypertension.
Dosage (summary)
20 mg three times a day.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Erythromycin
- Saquinavir
- Ketoconazole
- Itraconazole
- Bosentan
Contraindications
- Hypersensitivity to sildenafil
- Concurrent use with nitrates
- Severe hepatic impairment
- Severe renal impairment
- Blood pressure < 90/50 mmHg
Common side effects
- Headache
- Flushing
- Dyspepsia
- Back pain
- Diarrhoea
Counselling Points
- Take 6-8 hours apart
- Avoid nitrates
- Seek help for prolonged erections
- Monitor for vision changes
Serious warnings
- Risk of priapism
- Caution in cardiovascular disease
- Risk of NAION
Important Disclaimer
The Maklitio 20 mg Oral FC tablet. professional information leaflet below is the property of Macleods Pharmaceuticals Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
